Search | JOV | ARVO Journals

Showing 1 – 20 of 24

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Translational development of ikarovec’s bicistronic geographic atrophy lead AAV vector IKC159V through capsid and delivery route optimisation

Laura Vaux; Emily Warner; Kara Boyd; Peter Widdowson; Katie Binley; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):714.

ARVO Annual Meeting Abstract June 2024

IKC159V: A bicistronic AAV gene therapy that boosts expression of PEDF and sCD46 provides greater efficacy than anti-complement-only gene therapies in murine models of geographic atrophy

Andrew Osborne; Emily Warner; Laura Vaux; Kara Boyd; Peter Widdowson; Katie Binley

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5340.

ARVO Annual Meeting Abstract June 2023

Evaluation of a novel bi-cistronic gene therapy for the treatment of geographic atrophy

Andrew Osborne; Kara Boyd; Laura Vaux; Peter Stuart Widdowson; Katie Binley; Emily Warner

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):799.

ARVO Annual Meeting Abstract June 2023

Enhanced reduction of vascular leakage with a novel bi-cistronic gene therapy versus anti-VEGF for neovascular age-related macular degeneration

Emily Warner; Kara Boyd; Laura Vaux; Peter Stuart Widdowson; Katie Binley; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):771.

ARVO Annual Meeting Abstract June 2022

Novel bi-cistronic gene therapies for the treatment of dry age-related macular degeneration.

Kara Boyd; Katie Binley; Emily Francesca Warner; Andrew Osborne; Peter Stuart Widdowson

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):63 – A0036.

ARVO Annual Meeting Abstract June 2022

A Novel Bi-cistronic Gene Therapy for Neovascular Age-Related Macular Degeneration in Patients with Developing Subretinal Fibrosis

Andrew Osborne; Emily Francesca Warner; Kara Boyd; Peter Stuart Widdowson; Katie Binley

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):52 – A0025.

ARVO Annual Meeting Abstract June 2022

Novel Gene Therapy for the Regeneration of Schlemm's Canal for Patients with Ocular Hypertension

Katie Binley; Emily Francesca Warner; Kara Boyd; Peter Stuart Widdowson; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):50 – A0023.

ARVO Annual Meeting Abstract June 2022

Design of Novel Multi-Cistronic AAV2 Gene Therapy Constructs for the Treatment of Diabetic Macular Edema

Emily Francesca Warner; Kara Boyd; Michael Whitehead; Peter Stuart Widdowson; Katie Binley; Andrew Osborne

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3470.

ARVO Annual Meeting Abstract June 2020

Neutralising antibody responses to intravitreally delivered AAV2 and exosome-associated AAV2 vectors are associated with a failure of repeated gene transfer following vector readministration in the ipsilateral eye

Michael Whitehead; Andrew Osborne; Peter Widdowson; Patrick Yu-Wai-Man; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2441.

Anatomy and Pathology/Oncology November 2019

Expression of Developmentally Important Axon Guidance Cues in the Adult Optic Chiasm

PDF

Raquel Conceição; Rachel S. Evans; Craig S. Pearson; Barbara Hänzi; Andrew Osborne; Sarita S. Deshpande; Keith R. Martin; Amanda C. Barber
TAGS: adult, axon guidance, cues, optic chiasms, mice, brain, embryo
Invest. Ophthalmol. Vis. Sci.. 2019; 60(14):4727-4739. https://doi.org/10.1167/iovs.19-26732

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

QTA020V, a novel rAAV2 vector, reduces retinal ganglion cell body and axon loss in rats with laser-induced intraocular pressure elevation

Peter S Widdowson; Andrew Osborne; Tasneem Khatib; Katie Hall; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6132.

ARVO Annual Meeting Abstract July 2018

Sustained up-regulation of neuroprotective intracellular signalling pathways in retinal ganglion cells following intravitreal injection of QTA020V, a novel rAAV2 vector

Andrew Osborne; Lalana Songra; Peter S Widdowson; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6133.

ARVO Annual Meeting Abstract July 2018

Tau dysfunction in glaucoma: modulation of optic nerve axonal transport via gene therapy

Tasneem Khatib; Andrew Osborne; Peter S Widdowson; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3716.

ARVO Annual Meeting Abstract June 2017

Transgene expression, processing and activity following intravitreal Injection of QTA020V, a novel rAAV2 vector for retinal ganglion cell neuroprotection

Andrew Osborne; Peter S Widdowson; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2568.

ARVO Annual Meeting Abstract June 2017

Design and characterisation of an AAV2 vector aiming to achieve long term modulation of BDNF signalling as a treatment for glaucoma

Peter S Widdowson; Andrew Osborne; Alessia Tassoni; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2569.

ARVO Annual Meeting Abstract June 2017

QTA020V, a novel rAAV2 vector, delays retinal ganglion cell loss following optic nerve crush in the mouse

Keith R Martin; Andrew Osborne; Tasneem Khatib; Amanda Barber; George Kong; Peter S Widdowson

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2954.

ARVO Annual Meeting Abstract September 2016

Neuroprotection of human retinal ganglion cells by human mesenchymal stem cells and platelet derived growth factor

Andrew Osborne; Alessia Tassoni; Julie Sanderson; Keith R Martin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4401.

Glaucoma March 2016

Platelet-Derived Growth Factor Preserves Retinal Synapses in a Rat Model of Ocular Hypertension

PDF

Rachel S. Chong; Andrew Osborne; Raquel Conceição; Keith R. Martin
TAGS: ocular hypertension, platelet-derived growth factor, eye, retina, synapses, normal saline, saline solutions
Invest. Ophthalmol. Vis. Sci.. 2016; 57(3):842-852. https://doi.org/10.1167/iovs.15-17864

Includes: Supplemental Content

ARVO Annual Meeting Abstract April 2014

VEGF antagonism accelerates RGC apoptosis in diabetic mice; a potential role for VEGF in axonal transport

Richard Foxton; Andrew Osborne; Keith R Martin; Yin Shan Eric Ng; David T Shima

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):2181.

ARVO Annual Meeting Abstract March 2012

Activation of Stress Pathways by Ischaemia in Human Organotypic Retinal Cultures

Andrew Osborne; David C. Broadway; Julie Sanderson

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5325.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Translational development of ikarovec’s bicistronic geographic atrophy lead AAV vector IKC159V through capsid and delivery route optimisation

IKC159V: A bicistronic AAV gene therapy that boosts expression of PEDF and sCD46 provides greater efficacy than anti-complement-only gene therapies in murine models of geographic atrophy

Evaluation of a novel bi-cistronic gene therapy for the treatment of geographic atrophy

Enhanced reduction of vascular leakage with a novel bi-cistronic gene therapy versus anti-VEGF for neovascular age-related macular degeneration

Novel bi-cistronic gene therapies for the treatment of dry age-related macular degeneration.

A Novel Bi-cistronic Gene Therapy for Neovascular Age-Related Macular Degeneration in Patients with Developing Subretinal Fibrosis

Novel Gene Therapy for the Regeneration of Schlemm's Canal for Patients with Ocular Hypertension

Design of Novel Multi-Cistronic AAV2 Gene Therapy Constructs for the Treatment of Diabetic Macular Edema

Neutralising antibody responses to intravitreally delivered AAV2 and exosome-associated AAV2 vectors are associated with a failure of repeated gene transfer following vector readministration in the ipsilateral eye

Expression of Developmentally Important Axon Guidance Cues in the Adult Optic Chiasm

QTA020V, a novel rAAV2 vector, reduces retinal ganglion cell body and axon loss in rats with laser-induced intraocular pressure elevation

Sustained up-regulation of neuroprotective intracellular signalling pathways in retinal ganglion cells following intravitreal injection of QTA020V, a novel rAAV2 vector

Tau dysfunction in glaucoma: modulation of optic nerve axonal transport via gene therapy

Transgene expression, processing and activity following intravitreal Injection of QTA020V, a novel rAAV2 vector for retinal ganglion cell neuroprotection

Design and characterisation of an AAV2 vector aiming to achieve long term modulation of BDNF signalling as a treatment for glaucoma

QTA020V, a novel rAAV2 vector, delays retinal ganglion cell loss following optic nerve crush in the mouse

Neuroprotection of human retinal ganglion cells by human mesenchymal stem cells and platelet derived growth factor

Platelet-Derived Growth Factor Preserves Retinal Synapses in a Rat Model of Ocular Hypertension

VEGF antagonism accelerates RGC apoptosis in diabetic mice; a potential role for VEGF in axonal transport

Activation of Stress Pathways by Ischaemia in Human Organotypic Retinal Cultures

To View More...

You must be signed into an individual account to use this feature.